NasdaqGS:ENTABiotechs
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Enanta Pharmaceuticals slipped 2.1% to US$13.52 today, a modest pullback for a stock that has been roughly flat over the past week. The market is reacting to another loss making quarter, with Q3 basic earnings per share at a loss of US$0.67 and net income also in the red. The real story sits on a longer clock. Revenue over the past twelve months totals about US$65.3 million and analysts still model solid top line growth, which now has to be weighed against continued losses and recent...